Shares of Lupin Ltd ended flat on 4th December, even though the firm said it has signed an exclusive licensing agreement with US-based Valorum Biologics for its biosimilar Armlupeg (pegfilgrastim-unne).

Under the agreement, Valorum will handle the commercialisation and distribution of Amlupeg in the US. Meanwhile, Lupin will manufacture and supply the drug. Lupin will receive an upfront licence fee along with royalties on net sales.

Pegfilgrastim-unne is used to reduce the duration of neutropenia and the risk of febrile neutropenia in patients undergoing chemotherapy.

Lupin said it aims to strengthen its position in the US biosimilars market. It also plans to build on its global momentum in developing and commercialising key biosimilar medicines.

Earlier this week, the USFDA approved another version of Amlupeg — a 6mg / 0.6ml pre-filled syringe for subcutaneous use. It is a biosimilar to Neulasta. The product will be manufactured at Lupin’s biotech facility in Pune, which the US FDA inspected before approval.

At 3:30 PM, shares of Lupin Ltd ended 0.38% higher at Rs 2,088 on NSE.

Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!